The effect of proinflammatory cytokines on IL-17RA expression in NSCLC

详细信息    查看全文

• 作者：Qi Huang (1)
  Jiao Du (1) (2)
  Jinshuo Fan (1)
  Zhilei Lv (1)
  Xin Qian (1) (3)
  Xiuxiu Zhang (1)
  Jieli Han (1)
  Caiyun Chen (1) (4)
  Feng Wu (1)
  Yang Jin (1)
  
• 关键词：IL ; 17RA ; NSCLC ; IL ; 1β ; IL ; 6 ; IL ; 8 ; TNF ; α
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：31
• 期：9
• 全文大小：1,975 KB
• 参考文献：1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-9. CrossRef
  2. Rodriguez MA, Walters RS, Burke TW. 60 Years of survival outcomes at the University of Texas MD Anderson Cancer Center. Berlin: Springer; 2013.
  3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer decade of progress. CHEST J. 2002;122:1037-7. CrossRef
  4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-9. CrossRef
  5. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073-1. CrossRef
  6. Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang J-J, Kamimura D. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74:8-4. CrossRef
  7. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121:2373-0.
  8. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8:605-5. CrossRef
  9. Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets. 2011;15:1127-7. CrossRef
  10. Moseley T, Haudenschild D, Rose L, Reddi A. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155-4. CrossRef
  11. Yao Z, Fanslow WC, Seldin MF, Rousseau A-M, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995;3:811-1. CrossRef
  12. Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17:366-.
  13. Honorati MC, Neri S, Cattini L, Facchini A. IL-17 enhances the susceptibility of U-2OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 2003;133:344-.
  14. Honorati MC, Cattini L, Facchini A. Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res Clin Oncol. 2007;133:1017-1.
  15. Lindemann MJ, Hu Z, Benczik M, Liu KD, Gaffen SL. Differential regulation of the IL-17 receptor by γc cytokines inhibitory signaling by the phosphatidylinositol 3-kinase pathway. J Biol Chem. 2008;283:14100-.
  16. Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 2002;127:539-6.
  17. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP. Synergy of IL-21 and IL-15 in regulating CD8?+?T cell expansion and function. J Exp Med. 2005;201:139-8.
  18. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-2.
  19. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-1.
  20. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71:1-.
  21. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25:335-0.
  22. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal. 2011;23:1069-5.
  23. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem. 2006;281:24138-8.
  24. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19:281-.
  25. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-9.
  26. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol. 2011;186:3462-1.
  27. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348-4.
  28. He G, Zhang B, Zhang B, Qiao L, Tian Z, Zhai G, Xin X, Yang C, Liu P, Zhang Y, Xu L. Th17 cells and IL-17 are increased in patients with brain metastases from the primary lung cancer. Zhongguo Fei Ai Za Zhi. 2013;16:476-1.
  29. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A, Wald O. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE. 2011;6:e24856.
  30. Klimatsidas M, Anastasiadis K, Foroulis C, Tossios P, Bisiklis A, Papakonstantinou C, Rammos K. Elevated levels of anti inflammatory IL-10 and pro inflammatory IL-17 in malignant pleural effusions. J Cardiothorac Surg. 2012;7:104.
  31. Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett. 2012;148:144-0.
  32. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175:6177-9.
  33. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol. 2010;185:6348-4.
  34. Zhang GQ, Han F, Fang XZ. Ma XM [Expression of CD4(+) and IL-17, Foxp3 in non-small cell lung cancer and their correlation with microvessel density]. Zhonghua Zhong Liu Za Zhi. 2012;34:596-.
  35. Kaabachi W, Amor AB, Kaabachi S, Rafrafi A, Tizaoui K, Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine. 2014;66:23-.
  36. Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev. 2011;21:80-.
  37. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z, Zhu B. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci. 2010;101:2384-0.
  38. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986-7.
  39. Chen K-H, Weng M-S, Lin J-K. Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem Pharmacol. 2007;73:215-7.
  40. Chang K-T, Tsai C-M, Chiou Y-C, Chiu C-H, Jeng K-S, Huang C-YF. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2005;289:L446-3.
  41. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735-1.
  42. Lee IT, Lin CC, Wu YC, Yang CM. TNF-α induces matrix metalloproteinase-9 expression in A549 cells: role of TNFR1/TRAF2/PKCα-dependent signaling pathways. J Cell Physiol. 2010;224:454-4.
  
• 作者单位：Qi Huang (1)
  Jiao Du (1) (2)
  Jinshuo Fan (1)
  Zhilei Lv (1)
  Xin Qian (1) (3)
  Xiuxiu Zhang (1)
  Jieli Han (1)
  Caiyun Chen (1) (4)
  Feng Wu (1)
  Yang Jin (1)
  
  1. Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, People’s Republic of China
  2. Zhongshan Hospital, Xiamen University, 201-209 Hubin Road, Xiamen, 361004, Fujian, People’s Republic of China
  3. Department of Respiratory Medicine, Taihe Hospital, Hubei University of Medicine, No. 32, South Renmin Road, Shiyan, 442000, Hubei, People’s Republic of China
  4. Department of Respiratory, The First Hospital of Xi’an City, Xi’an, 710002, Shanxi, People’s Republic of China
  
• ISSN：1559-131X

文摘

Interleukin-17 receptor (IL-17RA) is essential for proinflammatory cytokine IL-17-mediated pathogenesis of various tumors. IL-17RA is upregulated by some proinflammatory cytokines such as IL-21 and IL-15 and downregulated by IL-2, while the effect of IL-1β, IL-6, IL-8, TNF-α on IL-17RA expression in non-small cell lung caner (NSCLC) remains unknown. Our findings revealed that IL-17RA mRNA was increased in NSCLC tissues compared with the corresponding peritumor tissues (P?=?0.0039) and high expression of IL-17RA protein in human NSCLC tissues was significantly associated with histological subtype, primary tumor size and clinical stages (P?=?0.033, 0.033 and 0.011, respectively). IL-17RA mRNA expression was positively related to IL-1β, IL-6, IL-8, TNF-α mRNA expression (P?=?0.013, 0.0001, 0.002 and 0.010 respectively) in NSCLC tissues. Furthermore, IL-1β, IL-6, IL-8, TNF-α upregulated IL-17RA mRNA and protein in A549 and H460 cells (all P?TNF-α promoted IL-17RA expression in NSCLC and they may involve in IL-17RA signaling in NSCLC.